Boomfish Wealth Group LLC Has $2.05 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Boomfish Wealth Group LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,092 shares of the pharmaceutical company’s stock after purchasing an additional 268 shares during the quarter. Boomfish Wealth Group LLC’s holdings in Vertex Pharmaceuticals were worth $2,051,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Mutual Advisors LLC grew its position in Vertex Pharmaceuticals by 0.6% in the third quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 21 shares during the last quarter. Daymark Wealth Partners LLC boosted its stake in shares of Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after purchasing an additional 22 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Vertex Pharmaceuticals by 5.7% during the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock valued at $191,000 after purchasing an additional 22 shares during the last quarter. Outlook Wealth Advisors LLC increased its position in Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock worth $415,000 after purchasing an additional 24 shares in the last quarter. Finally, Dunhill Financial LLC lifted its stake in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ VRTX opened at $438.40 on Friday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $434.56 and its 200 day simple moving average is $463.49. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the company posted $3.67 earnings per share. Vertex Pharmaceuticals’s revenue was up 11.6% compared to the same quarter last year. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on VRTX shares. Morgan Stanley upped their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Bank of America dropped their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Citigroup began coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, January 24th. Finally, Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $494.76.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.